VAXXAS
LIVE

Serial Number

79287747

Owner

Vaxxas Pty Ltd

Attorney

Gregory M. Krakau

Filing Date

Apr 20, 2020

Add to watchlist:

No watchlists yet
View on USPTO

VAXXAS Trademark

Serial Number: 79287747 • Registration: 6413534

VAXXAS is a trademark filed by Vaxxas Pty Ltd on April 20, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Vaxxas Pty Ltd

c/- One Ventures Management
Sydney, NSW 2000 , AU

Entity Type: 99

Trademark Details

Filing Date

April 20, 2020

Registration Date

July 13, 2021

Published for Opposition

April 27, 2021

Goods & Services

Custom manufacturing services in the field of drug delivery patches; custom manufacture of medical devices, pharmaceuticals, diagnostic tests and testing kits; custom manufacture of micro-projection array patches; custom manufacture of drug delivery devices and apparatus; custom manufacture of transdermal drug delivery devices and apparatus; custom manufacture of intradermal drug delivery devices and apparatus; custom manufacture of micro-projection drug delivery devices and apparatus; advisory, consultancy and information services in relation to all of the aforesaid

Pharmaceutical, medicinal and therapeutic preparations for human and veterinary use for the treatment of infectious disease, allergies and oncology; vaccines; vaccine preparations; diagnostic preparations for medical or veterinary purposes; biological specimens, blood and plasma for human medical diagnostics and analysis; transdermal patches, bandages, poultices and medical dressings impregnated with vaccines; patches, bandages, poultices and medical dressings impregnated with vaccines; transdermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations for treating infectious disease, allergies and oncology contained in transdermal patches; skin patches for the transdermal delivery of pharmaceuticals for use in the treatment of infectious disease, allergies and oncology; transdermal patches for administering pharmaceuticals for use in the treatment of infectious disease, allergies and oncology and vaccines; intradermal patches for use in the medical treatment of infectious disease, allergies and oncology; intradermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations contained in intradermal patches for use in the medical treatment of infectious disease, allergies and oncology; skin patches for the intradermal delivery of pharmaceuticals for use in the treatment of infectious disease, allergies and oncology; intradermal patches for medical treatment for administering pharmaceuticals for use in the medical treatment of infectious disease, allergies and oncology and vaccines; micro-projection array patches for medical purposes impregnated with vaccines; structural parts and fittings for the aforesaid goods

Legal services relating to the exploitation and licensing of intellectual property and technology; licensing of medical technology; legal services relating to the licensing of research and development of products; advisory, consultancy and information services in relation to all of the aforesaid

Medical, medical clinic, and healthcare services relating to vaccines; medical and veterinary consultancy; medical testing for diagnostic or treatment purposes; advisory, consultancy and information services in relation to all of the aforesaid

Surgical and medical apparatus and instruments, namely, vaccine and drug delivery microneedle array patches sold without medication; drug delivery devices and apparatus, namely, hermetically sealed applicators containing patches for applying vaccine sold without medication; drug delivery devices sold empty, namely, uncoated patches sold without medication; transdermal drug delivery devices and apparatus, namely, transdermal drug delivery patches sold without medication; intradermal drug delivery devices and apparatus, namely, intradermal drug delivery patches sold without medication; micro-projection drug delivery devices and apparatus, namely, drug delivery patches sold without medication; structural parts and fittings for the aforesaid goods

Research, design and development services in the field of medical apparatus and instruments; medical research, design and development services in the field of drug delivery devices; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; drug discovery; vaccine screening, namely, safety testing of vaccines; scientific and technological research services related to immunopharmaceuticals and vaccines; biological research, clinical research in the field of immunology, vaccines, and medical research; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical and biochemical analysis services; medical and scientific research; pharmaceutical research services; laboratory testing services in the field of vaccines, pharmaceuticals; laboratory research in the fields of biotechnology, microbiology, molecular biology, nanotechnology analytical chemistry, biochemistry, medicinal chemistry and drug development; technology services, namely, design and development of computer hardware; scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; research and development services in the field of antibodies; antibody generation services being research and development services; diagnostic and research services and screening in the field of infectious disease, allergies and oncology for medical research purposes; diagnostic testing services in the field of medical apparatus and instruments; medical research services; advisory services relating to diagnostic testing of products for quality control and safety purposes; research and development of products; advisory, consultancy and information services in relation to all of the aforesaid

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Oct 10, 2023 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Sep 5, 2023 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 30, 2023 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 25, 2022 APRE
CORRECTION UNDER SECTION 7 - PROCESSED
Mar 25, 2022 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 24, 2022 APRE
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 28, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 9, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 9, 2021 FIMP
TEAS SECTION 7 REQUEST RECEIVED
Oct 31, 2021 ES7R
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 13, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 13, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 27, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 27, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Apr 24, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 7, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 7, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 7, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 23, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 23, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 22, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 22, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 17, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 17, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 17, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 24, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 10, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 10, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 10, 2020 CNRT
REFUSAL PROCESSED BY IB
Aug 30, 2020 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 20, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 19, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 19, 2020 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 11, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 11, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 20, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 19, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 11, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 24, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 20, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 18, 2020 REPR